RESEARKA

Several unresolved questions constrain the interpretation of PCSK9 inhibitors longevity evidence for aging populations. First, the mechanistic translation from lipid lowering to vascular aging attenuation remains poorly characterized: while preclinical studies suggest PCSK9 inhibition may reduce inflammatory biomarkers and improve endothelial function (Rehues 2023), human data are limited to short-term biomarker endpoints. Second, population specificity is a major gap: most trials enrolled middle-aged adults with established cardiovascular disease, and the applicability to frail, multimorbid, or very old individuals remains uncertain (Theodorou 2025). Third, dose-response and duration effects on aging outcomes are unknown, with existing trials typically limited to 2-5 years of follow-up. The PCSK9 inhibitors longevity hypothesis thus faces a translation gap between cardiometabolic efficacy and demonstrated geroprotective benefit.

Citation Support

• source_1 Ma 2025
• source_2 Schwartz 2021
• source_3 Lehrke 2024
• source_4 Imran 2023
• source_5 Faraidy 2023